News
Merck delivers vital data on evobrutinib
Merck has announced updated four-year safety and efficacy data for its relapsing multiple sclerosis (RMS) therapy, evobrutinib.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Merck has announced updated four-year safety and efficacy data for its relapsing multiple sclerosis (RMS) therapy, evobrutinib.